HDAT Journal

Editorial

At follow-up in 1982, the actuarial 10-year survival rates for patients with unilateral and bilateral atherosclerotic disease were 65% and 48%, respectively [[1]]. The time at which patients with atherosclerosis or thrombosis thus lived so little seems far away, and one can only rejoice. Nowadays, it is common to encounter patients that have been living for more than ten, fifteen or even twenty years, with their disease. After nearly forty years of which the coronary angioplasty has constituted the only recourse, some teams present the case of patients for who up to fifteen lines of different treatments are described.

This disease is now facing a real therapeutic and physic pathologic revolution materialized by the development of therapeutic tools to reduce the risk of blood clots, prevent diseases related to atherosclerosis, reduce risk factors in an effort to reduce or eliminate plate accumulation, improve symptoms, and expand or bypassing arteries obstructed by plaque. The research community is dissecting and penetrating in the intimacy of the atherosclerotic plaque, the endothelial microenvironment, but also the immune system in the surrounding area. At the same time, clinical research is progressing at an extraordinary rate, and major international studies have been completed in just a few months after several hundred patients have been included in the development of new antithrombotic tools.

The latest ASH conference, which was held in San-Diego from December 3^rd to 6^th, 2016, featured a record number of communications related to new scientific discoveries which have led to the development of new therapeutic strategies to treat Thrombosis and Hemostasis disorders. In addition, disorders of platelet homeostasis and function in acute and chronic diseases were also addressed in this congress. New interesting discoveries concerning the biological functions of platelets in vascular diseases have been presented focusing on their role in human infectious, inflammatory and thrombotic diseases. A particular emphasis was placed on the clinical implications of the platelets’ functional deregulation in systemic diseases. Finally, a session was dedicated to the issuance of recommendations on the management of patients at risk for thrombosis due to obesity, inflammatory pathologies such as inflammatory bowel disease, kidney or liver disease and cancer.

In the current context of fundamental research, there is a large number of scientific references in the field of haematological diseases. And this is not surprising, given the large number of clinical and scientific challenges and research in the field. Nowadays, it is essential more than ever to reduce the uncertainty inherent to the results of mass, of clinical or fundamental nature, using the latest and most relevant scientific knowledge.

The use of this knowledge, as the core of research environments, constitutes a key factor in the evolution of scientific practices and its results. Thus; patients, caregivers, students and more broadly, health systems and organizations are potential beneficiaries of the adoption by researchers of an ethical and reproducible research based on evidence and scientifically validated results.

Gavin publisher is, therefore, aiming to be a part of this effort to support and accompany the process of affirming research on hematological diseases and their treatments within the existing literature ocean by creating an innovative publication review in the field, namely the journal of "Hematological Diseases and Therapies". The objectives of this new journal are to contribute to the development and dissemination of new scientific data and to promote research in hematological sciences. It was also designed to optimize the visibility and the impact of work while putting within the hands of its readers the update studies and their assessment.

This journal builds on the global scientific community, which promotes research in this field of ​​knowledge. The members of the editorial board as well as the team of evaluators are all experts in the field and operate in a variety of international contexts and belong to highly qualified institutions. We wished to find in this review the diversity that characterizes the research as it is practiced in the world. In each issue, the articles will highlight diversified research topics and practice contexts in different parts of the world. This ambitious goal will enable the establishment of a new scientific culture, guaranteeing the relevance, effectiveness, quality, safety, and efficiency of care.

We welcome you to the journal of "Hematological Diseases and Therapies" and are happy to enable you to explore the pluralistic world of hematological science research in full expansion.

1.  Bardram L, Helgstrand U, Bentzen MH, Buchardt HJ, Hansen, et al. (1985) Late Results after Surgical Treatment of Renovascular Hypertension. Ann Surg 201: 219-224.